What is Pontifax's most recent fund close?

Pontifax closed Fund 6 in October 2020, raising $404 million.

What was a significant exit for Pontifax in the last two years?

In February 2026, Pontifax saw CathWorks acquired by Medtronic for $585 million. Another notable exit was V-Wave, acquired by Johnson & Johnson for $600 million in August 2024.

Which sectors does Pontifax primarily focus on for investments?

Pontifax primarily focuses on Health Tech & Life Sciences, with 34 portfolio companies in this sector.

Can you name some of Pontifax's public portfolio companies?

Pontifax has several public portfolio companies, including 89bio, Eloxx Pharmaceuticals, and UroGen Pharma.

What is the investment stage focus for Pontifax?

Pontifax invests across various stages, including Seed, A Round, B Round, C Round, D Round, E Round, F Round, and G Round.

Who are the co-founders of Pontifax?

The co-founders of Pontifax are Tomer Kariv, who serves as Co-Founder & CEO, and Ran Nussbaum, Co-founder & Managing Partner.

What was the size of Pontifax's Fund 5?

Pontifax closed Fund 5 in January 2018, raising $240 million.

Has Pontifax had any recent IPOs in its portfolio?

In November 2019, 89bio went public on NASDAQ, raising $85 million. LogicBio Therapeutics also went public on NASDAQ in October 2018, raising $70 million.

Pontifax

Pontifax is an Israeli venture capital firm focused on life sciences and healthcare, investing in breakthrough innovations across all development stages.

Venture Capital Active Herzliya, Israel Est. 2004

Visit website ↗ LinkedIn

Last updated 2026-07-20

Raised $404M Undisclosed Round, Oct 2020
Raised $240M Undisclosed Round, Jan 2018

Portfolio

in our dataset

Rounds participated

Rounds led

Rounds' value

$208.5M

total disclosed, rounds participated

Stages

Seed, Pre-Seed, F Round, D Round, E Round, G Round, B Round, A Round, C Round

About

Founded in 2004, Pontifax is a healthcare-dedicated venture capital firm with approximately $1.2 billion under management. The firm focuses exclusively on life sciences and healthcare, seeking transformative, cutting-edge technologies at all development stages. Pontifax invests in breakthrough innovation regardless of therapeutic area or development stage, establishing its own companies and partnering with existing management to nurture startups to maturity. The firm takes a hands-on approach in its portfolio management, providing strategic guidance, network access, and capital markets/M&A support. Pontifax's portfolio comprises about 100 companies that develop breakthrough solutions to substantial unmet needs. The firm also has an AgTech arm, Pontifax Global Food and Agriculture.

Portfolio · 13

OCON Therapeutics

Spherical Intrauterine Drug Delivery Platform

Led ★ 3 rounds $9.5M committed Latest: 2020-12

Metabomed

Target-inhibiting Anticancer Drugs

2 rounds $30.5M committed Latest: 2019-12

Pi Therapeutics

Inhibitors for Cancer Treatment

Led ★ 2 rounds $19.7M committed Latest: 2019-05

Tisbury Pharmaceuticals

Open-angle Glaucoma Treatment

1 round $32.0M committed Latest: 2017-06

LogicBio Therapeutics

Gene Therapy for Genetic and Infectious Diseases

1 round $45.0M committed Latest: 2017-06

ARTSaVIT

Cancer Apoptosis Technology

1 round Latest: 2017-01

Nutrinia

Neonatal Gastrointestinal Treatment

2 rounds $42.0M committed Latest: 2016-08

Avraham Pharmaceuticals

Prevention of Neurodegenerative Disorders

3 rounds $17.5M committed Latest: 2016-02

BioCEP

Cell Isolation Platform

1 round $5.3M committed Latest: 2014-02

HeadSense

Noninvasive Multiparameter Brain Monitoring

1 round Latest: 2013-07

Quiet Therapeutics

Anticancer Therapeutics Using Nanoparticles and Biomarkers

1 round $5.5M committed Latest: 2013-01

InsuLine Medical

Insulin Treatment Method

1 round $1.5M committed Latest: 2012-04

ProMining Therapeutics

Drug Discovery Platform for Novel Oral Drugs

1 round

Investment activity

12 portfolio exits on record.

Portfolio by sector

Health Tech & Life Sciences34

Undisclosed2

Business Software1

Funds · 6

6 — $404M Oct 2020
5 — $240M Jan 2018
4 — $175M Dec 2016
3 — $88M Jan 2011
2 — $80M Jan 2008
1 — $36M Dec 2004

Q&A

What is Pontifax's most recent fund close?: Pontifax closed Fund 6 in October 2020, raising $404 million.
What was a significant exit for Pontifax in the last two years?: In February 2026, Pontifax saw CathWorks acquired by Medtronic for $585 million. Another notable exit was V-Wave, acquired by Johnson & Johnson for $600 million in August 2024.
Which sectors does Pontifax primarily focus on for investments?: Pontifax primarily focuses on Health Tech & Life Sciences, with 34 portfolio companies in this sector.
Can you name some of Pontifax's public portfolio companies?: Pontifax has several public portfolio companies, including 89bio, Eloxx Pharmaceuticals, and UroGen Pharma.
What is the investment stage focus for Pontifax?: Pontifax invests across various stages, including Seed, A Round, B Round, C Round, D Round, E Round, F Round, and G Round.
Who are the co-founders of Pontifax?: The co-founders of Pontifax are Tomer Kariv, who serves as Co-Founder & CEO, and Ran Nussbaum, Co-founder & Managing Partner.
What was the size of Pontifax's Fund 5?: Pontifax closed Fund 5 in January 2018, raising $240 million.
Has Pontifax had any recent IPOs in its portfolio?: In November 2019, 89bio went public on NASDAQ, raising $85 million. LogicBio Therapeutics also went public on NASDAQ in October 2018, raising $70 million.

Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Website	pontifax.com/
LinkedIn	linkedin.com/company/10232239

Identifiers & details

Founded	2004

Radar intelligence

Publications (Crossref)

Works	1

Web history (Wayback)

Domain	pontifax.com

Certificate / subdomain footprint

Subdomains	5